In December, the FDA approved the first oral antiviral https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. A limited number of FQHCs in Pennsylvania have begun to receive a supply of oral antivirals. Pennsylvania locations with oral antivirals obtained through the PA Department of health can be found at: https://www.health.pa.gov/topics/disease/coronavirus/Pages/Prevention-Treatment.aspx#oral Scroll down the page and note there are separate links for Mulnupiravir providers and Paxlovid providers. Individuals can also search by address using this therapeutics map: https://protect-public.hhs.gov/pages/therapeutics-distribution In addition, around 200 health centers nationwide, including seven in Pennsylvania, have been invited to participate in the HRSA program to distribute oral antivirals. As supply increases, oral AVs should be a more accessible solution, but supply is currently very limited in both programs.
